The year of the brand’s birth. The Senior Researcher of Altai Research and Production Center Larisa Prokopieva opens the company Evalar, staffed with just 12 people.
First products are manufactured. The first patent for industrial technology of processing the legendary natural product Altai Mumiyo is obtained.
The production of MCC Ankir-B tablets begins, providing the young enterprise with a huge increase in sales and access to the pharmaceutical market in Russia.
Evalar starts developing a new activity, building its own pharmacy chain in the Altai Territory. The first pharmacies open in Biysk. The company’s annual turnover is just 17 million rubles.
The company begins to cultivate its own plantations in the foothills of Altai.
Evalar brings the equipment of its enterprise in accordance with the international standard GMP, years ahead of all pharmaceutical companies in the country. Its portfolio includes more than 90 SKU.
The production unit for tablets is put into operation. The company introduces the international standard HACCP. The company obtains a license for modern production of extracts from herbal medicinal raw materials (with the production capacity of 5 tons of dry extracts per month).
Evalar representative office opens in Moscow.
The production unit for galenicals is put into operation. The company’s staff includes 1000 people.
Start of the development of the company’s chain of pharmacies Evalar in Moscow.
The Company obtains the certificate on conformity of the manufacturing facilities to the international standard of quality ISO 9001: 2008.
Evalar gets the certificate for compliance with the GMP quality standard, issued by the International division of the National Sanitary Foundation of the United States (NSF International).
Evalar obtains the certificate of conformity with the GMP from the Ministry of Health of Australia and enters the country’s local market. Representative offices open in Paris and Sydney. The total number of company’s employees exceeds 1300 people. The portfolio of the Altai manufacturer includes more than 300 SKU. Evalar expands its production twofold and builds another plant. The investments in the project exceed $100 million. The company continues to hold the leading position in the Russian market of natural medicinal products. The pharmacy chain Evalar has about 60 pharmacies in large cities of Russia. The annual turnover of the joint-stock company is close to 10 billion rubles.
Evalar celebrates its 25th anniversary. Evalar is included in the TOP-5 of the largest domestic pharmaceutical manufacturers. The company is building a second manufacturing plant in the Altai Territory, with a productive capacity of 6 billion tablets and capsules per year.
The company receives a GMP certificate following the results of a national audit carried out by the Ministry of Industry and Trade of the Russian Federation for compliance with the Rules of Good Manufacturing Practice (Order No. 916 of the Ministry of Industry and Trade of 14.06.13).